Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)

Journal of Medical Virology

Volumn 90, Issue 2, 2018, Pages 304-312

  Wehmeyer, Malte H ^a   Ingiliz, Patrick ^b   Christensen, Stefan ^c   Hueppe, Dietrich ^d   Lutz, Thomas ^e   Simon, Karl Georg ^f   Schewe, Knud ^g   Boesecke, Christoph ^h   Baumgarten, Axel ^b   Busch, Heiner ^c   Rockstroh, Juergen ^h   Schmutz, Guenther ⁱ   Kimhofer, Torben ^j   Berger, Florian ⁱ   Mauss, Stefan ⁱ   Schulze zur Wiesch, Julian ^a,k  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Center for Infectiology (CIB)   (Germany)

^c CIM Infectious diseases   (Germany)

^d Practice for Gastroenterology   (Germany)

^e Infektiologikum   (Germany)

^f Gastroenterology Practice   (Germany)

^g Infektionsmedizinisches Centrum Hamburg   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ Center for HIV and Hepatogastroenterology   (Germany)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k Center for Infection Research   (Germany)

more..

Author keywords

daclatasvir; direct acting antivirals; HCV; HIV; ledipasvir

Indexed keywords

DACLATASVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PROSPECTIVE STUDY; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; AGED; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85037709245     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24903     Document Type: Article

References (26)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61:S45–S57.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61:77–87.
3. Robaeys G, Rob B, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016; 65:1094–1103.
4. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype infection: results of the HCV-TARGET study. Clin Infect Dis. 2016; 63:776–783.
5. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology. 2016; 151:457–471.
6. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014; 312:353–361.
7. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015; 385:1098–1106.
8. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015; 149:1642–1470.
9. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotypes 2 or 3 and cirrhosis. Hepatology. 2015; 61:769–775.
10. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Eng J Med. 2013; 368:1867–1877.
11. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370:1993–2001.
12. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370:211–221.
13. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: aLLY-3 phase III study. Hepatology. 2015; 61:1127–1135.
14. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016; 63:1430–1441.
15. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015; 149:1454–1461.
16. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015; 373:2608–2617.
17. Schulze zur Wiesch J, Pudelski N, Hoepner L, et al. “Real-life” comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. Hepatology. 2011; 53:1405–1406.
18. Heidrich B, Cordes HJ, Klinker H, et al. Treatment extension of pegylated interferon alpha and ribavirin does not improve SVR in patients with genotypes 2/3 without rapid virological response (OPTEX trial): a prospective, randomized, two-arm, multicentre phase IV trial. PLoS ONE. 2015; 10:e0128069.
19. Berden FAC, Aaldering BRRZ, Groenewoud H, IntHout J, Kievit W, Drenth JPH. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017; 15:349–359.
20. Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir-sofosbuvir plus ribavirin in treatment-naive patients with hepatitis c virus genotype 3 infection: an open-label study. Clin Infect Dis. 2017; 65:13–19.https://doi.org/10.1093/cid/cix289
21. Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol. 2016; 65:473–482.
22. Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals—results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016; 63:1320–1324.
23. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373:705–713.
24. Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2017; 18:284–291.
25. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sosfosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373:714–725.
26. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015; 162:619–629.